Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
- NCIt
- C96963
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Variants & evidence
282 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RB1 Overexpression1 | ||||||||
| Doxorubicin + Fluorouracil + Gemcitabine + MitomycinSubstitutes | Pancreatic Adenocarcinoma | Predictive | D | Supports Resistance | 2 | accepted | EID1324In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depl… (full text at CIViC) PMID 11792751 · Plath et al., 2002 · Open in CIViC | civic |
| RHOA MUTATION1 | ||||||||
| (prognostic) | Gastric CarcinomaALIAS | Prognostic | E | Supports Poor Outcome | 2 | accepted | EID1683285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles. RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognos… (full text at CIViC) PMID 27313181 · Rokutan et al., 2016 · Open in CIViC | civic |
| RICTOR Amplification1 | ||||||||
| Vistusertib | Gastric Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID1915Tumor samples from 640 patients with metastatic solid tumors were prospectively analyzed with a next-generation sequencing assay to identify molecular targets. 13 (2%) of 640 patients had a RICTOR-aam… (full text at CIViC) PMID 28028034 · Kim et al., 2017 · Open in CIViC | civic |
| RPS6 PHOSPHORYLATION1 | ||||||||
| Everolimus | Gastric Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID93054 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser24… (full text at CIViC) PMID 22343617 · Yoon et al., 2012 · Open in CIViC | civic |
| SLC29A1 Overexpression1 | ||||||||
| Gemcitabine | Pancreatic Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID10145Surgically resected PDACs were used to create tissue microarrays, which were scored for antibody staining of hENT1 (SLC29A1). For patients treated with gemcitabine (n=243), high levels of hENT1 were a… (full text at CIViC) PMID 22705007 · Maréchal et al., 2012 · Open in CIViC | civic |
| ROS1 Fusion1 | ||||||||
| Crizotinib | Pancreatic Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11651In this case report of a single patient with pancreatic adenocarcinoma was found to harbour a SLC4A4::ROS1 fusion by NGS analysis. Based on the presence of the ROS1 fusion the patient was initiated on… (full text at CIViC) PMID 37079858 · Reutter et al., 2023 · Open in CIViC | civic |
| SMAD4 Expression1 | ||||||||
| (prognostic) | Pancreatic Ductal Adenocarcinoma | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1306In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was ass… (full text at CIViC) PMID 11751510 · Tascilar et al., 2001 · Open in CIViC | civic |
| SMAD4 Mutation1 | ||||||||
| (prognostic) | Pancreatic Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID511In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients. PMID 19584151 · Blackford et al., 2009 · Open in CIViC | civic |
| SPRY2 UNDEREXPRESSION1 | ||||||||
| (prognostic) | Gastric Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID6455The correlation between FGFR2/SPRY2 and clinicopathologic factors was analyzed by Chi-square to screen the FGFR2/SPRY2-relevant factors. SPRY2 low expression was demonstrated to be significantly assoc… (full text at CIViC) PMID 28002800 · Xu et al., 2017 · Open in CIViC | civic |
| STK11 Loss1 | ||||||||
| Roflumilast | Pancreatic Ductal Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID12555In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC) PMID 38461159 · Zhang et al., 2024 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Ceritinib | Colon Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5952Patients with metastatic colorectal cancer with STRN-ALK fusion, sporadic microsatellite instability high (MSI-H) and KRAS R164Q received ALK inhibitor ceritinib. After pts received ceritinib perinumb… (full text at CIViC) PMID 26933125 · Yakirevich et al., 2016 · Open in CIViC | civic |
| High2 | ||||||||
| (prognostic) | Rectal AdenocarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID13211This study evaluated genomic biomarkers associated with treatment response and clinical outcomes in patients with locally advanced rectal adenocarcinoma (LARC) treated with neoadjuvant chemoradiation … (full text at CIViC) PMID 37260182 · Lee et al., 2023 · Open in CIViC | civic |
| 〃 | Colon Adenocarcinoma | Prognostic | B | Supports Better Outcome | 3 | accepted | EID13242In a single-center observational study of 102 patients with microsatellite stable (MSS) metastatic colon cancer receiving standard treatments, high tumor mutational burden (TMB ≥10 mutations/Mb) was a… (full text at CIViC) PMID 39639373 · Di Mauro et al., 2024 · Open in CIViC | civic |
| TP53 Mutation3 | ||||||||
| (prognostic) | Esophageal Squamous Cell CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID519In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival. PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC | civic |
| Chemotherapy | Gastric Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID850In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.7… (full text at CIViC) PMID 24740294 · Xu et al., 2014 · Open in CIViC | civic |
| Cisplatin + Doxorubicin + EtoposideCombination | Gastric CarcinomaALIAS | |||||||
| TP53 R175H1 | ||||||||
| EAP Protocol | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | — | accepted | EID2310In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 R213P1 | ||||||||
| EAP Protocol | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | — | accepted | EID2819In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 R273C1 | ||||||||
| Cisplatin + Etoposide + MitomycinCombination | Gastric CarcinomaALIAS | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID2292A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score w… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 R282L1 | ||||||||
| EAP Protocol | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | — | accepted | EID2818In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TP53 V197E1 | ||||||||
| (predisposing) | Esophageal Squamous Cell CarcinomaALIAS | Predisposing | C | Supports Predisposition | 1 | submitted | EID9846Analysis of 77 esophageal squamous cell carcinoma tumor and normal samples for germline mutations revealed a rare TP53 V197E variant in a single patient. The V197E mutation is in the DNA-binding domai… (full text at CIViC) PMID 30833958 · Deng et al., 2019 · Open in CIViC | civic |
| TP53 Wildtype1 | ||||||||
| Chemotherapy | Esophageal Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID906Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 … (full text at CIViC) PMID 23515910 · Zhang et al., 2013 · Open in CIViC | civic |
| TP53 Y220C1 | ||||||||
| Cisplatin + Etoposide + MitomycinCombination | Gastric CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID2306A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric … (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC | civic |
| TYMS Overexpression1 | ||||||||
| Raltitrexed | Gastric Adenocarcinoma | Predictive | B | Supports Resistance | 2 | accepted | EID929In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively). PMID 22422354 · Shen et al., 2012 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Crizotinib | Colorectal Adenocarcinoma | Predictive | E | Supports Sensitivity Response | 1 | accepted | EID133426 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potenti… (full text at CIViC) PMID 19737969 · Lin et al., 2009 · Open in CIViC | civic |
| VEGFC Overexpression1 | ||||||||
| Sunitinib | Hepatocellular Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7987Phase 2 trial of adult hepatocellular patients treated with sunitinib analyzed how baseline concentration of different soluble VEGF proteins predict overall survival (OS) and time to progression (TTP)… (full text at CIViC) PMID 21787417 · Harmon et al., 2011 · Open in CIViC | civic |
| NRG1 Fusion3 | ||||||||
| Afatinib | Pancreatic Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID6273In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC) PMID 29802158 · Heining et al., 2018 · Open in CIViC | civic |
| Erlotinib + PertuzumabCombination | Pancreatic Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7534In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC) PMID 29802158 · Heining et al., 2018 · Open in CIViC | civic |
| Zenocutuzumab-zbco | Pancreatic Adenocarcinoma | Predictive | A | |||||
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID6052In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, two patient with cholangiocarcinoma with NTRK fusion was enrolled. One of the two patient showed PR. PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| ROS1 Fusion1 | ||||||||
| Crizotinib | Colorectal Adenocarcinoma | Predictive | E | Supports Sensitivity Response | 2 | accepted | EID1301A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Bre… (full text at CIViC) PMID 24296758 · Aisner et al., 2014 · Open in CIViC | civic |
| WEE1 Overexpression1 | ||||||||
| Adavosertib | Esophageal Squamous Cell CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID9232Within a preclinical study the inhibitory effects of AZD1775 in esophageal squamous cell carcinoma (ESCC) was demonstrated in both in vitro and in-vivo samples that predominantly displayed high expres… (full text at CIViC) PMID 31427973 · Bi et al., 2019 · Open in CIViC | civic |
Data updated 12 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Predictive |
| C |
| Supports Sensitivity Response |
| 1 |
| accepted |
EID2820In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC |
| civic |
| Supports Sensitivity Response |
| 4 |
| accepted |
EID12247On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for adults with advanced, unresectable, or metastatic non-small cell lun… (full text at CIViC) PMID 39908431 · Schram et al., 2025 · Open in CIViC |
| civic |